摘要
目的：探讨多西他赛联合顺铂治疗中晚期非小细胞肺癌和乳腺癌的疗效及毒副作用。方法：中晚期非小细胞肺癌43例和乳腺癌32例,应用多西他赛联合顺铂方案（多西他赛70 mg/m^2d1,顺铂40 mg d2-4,3周为1疗程）化疗2个疗程以上评价疗效。结果：非小细胞肺癌的缓解率（完全缓解＋部分缓解）为27.9%,乳腺癌为31.3%;主要毒副作用均为白细胞减少和恶心、呕吐、肌肉酸痛、发热等,且Ⅳ度少见,未见明显肝肾毒性,差异均无统计学意义（P〉0.05）。结论：多西他赛联合顺铂治疗中晚期非小细胞肺癌和乳腺癌的疗效和安全性均较好,毒副反应可以耐受。
Objective：The study was to evaluate the efficacy and tolerability of doeetaxel plus cisplatin in the treatment of non-small cell lung cancer and breast cancer. Methods：Seventy-five patients were received docetaxel 70 mg/m^2 d1 plus cisplatin 40 mg d2 -4, and the plan was repeated every 3 weeks. All the patients had to received at least 2 cycles of chemotherapy. Results： The response rate of the study （ CR ＋ PR） was 29.3% （ non-small lung cancer was 27.9%, breast cancer was 31.3% ）. The main toxicities were myelo suppression, alimentary canal reactions, muscle soreness and fever, and the rate of grade Ⅳ was low. Conclusions： Docetaxel plus cisplatin can work effectively and safely in the treatment of advanced non-small lung cancer and breast cancer, and the toxicity can be toleranced.
出处
《蚌埠医学院学报》
CAS
2009年第8期699-701,共3页
Journal of Bengbu Medical College
关键词
肺肿瘤
乳腺肿瘤
肿瘤/药物疗法
多西他赛
顺铂
lung neoplasms
breast neoplasms
neoplasms/drug therapy
docetaxel
cisplatin
